PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus from 15 analysts (10 buy, 4 hold, 1 sell) with an average 1‑year price target of $82.79.
• PTC sharply missed quarterly estimates, reporting EPS of ($1.67) vs. ($0.21) expected and revenue of $164.7M vs. $281.5M expected, with revenue down 22.7% year‑over‑year and sell‑side forecasts calling for -4.52 EPS for the year.
• Insider selling totaled 137,755 shares (~$9.95M) in the last 90 days (insiders own 5.5%), while the stock trades around $66.42 with a 1‑year range of $35.95–$87.50 and a market cap of $5.5B.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $82.7857.

Several brokerages have recently issued reports on PTCT. Cantor Fitzgerald reissued an "overweight" rating on shares of PTC Therapeutics in a research report on Friday, February 20th. Royal Bank Of Canada reduced their target price on shares of PTC Therapeutics from $87.00 to $82.00 and set a "sector perform" rating for the company in a research note on Friday, February 20th. Wells Fargo & Company lowered their target price on PTC Therapeutics from $93.00 to $86.00 and set an "overweight" rating for the company in a report on Friday, February 20th. Weiss Ratings reissued a "hold (c)" rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Finally, TD Cowen restated a "hold" rating on shares of PTC Therapeutics in a report on Thursday, January 29th.

PTC Therapeutics Trading Up 1.7%

NASDAQ:PTCT opened at $66.42 on Tuesday. PTC Therapeutics has a 1 year low of $35.95 and a 1 year high of $87.50. The stock has a 50-day moving average price of $70.48 and a two-hundred day moving average price of $70.64. The stock has a market cap of $5.50 billion, a price-to-earnings ratio of 8.58 and a beta of 0.51.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The business had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The company's revenue for the quarter was down 22.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.85) EPS. Sell-side analysts forecast that PTC Therapeutics will post -4.52 earnings per share for the current year.

Insider Buying and Selling at PTC Therapeutics

In other news, Director Stephanie Okey sold 15,167 shares of the firm's stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $70.00, for a total transaction of $1,061,690.00. Following the completion of the transaction, the director directly owned 8,000 shares of the company's stock, valued at $560,000. This trade represents a 65.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of PTC Therapeutics stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $76.35, for a total transaction of $916,200.00. Following the completion of the sale, the director owned 18,500 shares in the company, valued at $1,412,475. This trade represents a 39.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 137,755 shares of company stock valued at $9,945,471 in the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PTCT. WCM Investment Management LLC acquired a new position in PTC Therapeutics during the third quarter worth $8,919,000. Prudential Financial Inc. lifted its stake in PTC Therapeutics by 35.5% in the second quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company's stock valued at $4,115,000 after acquiring an additional 22,060 shares during the last quarter. Sector Gamma AS lifted its stake in PTC Therapeutics by 28.0% in the third quarter. Sector Gamma AS now owns 118,112 shares of the biopharmaceutical company's stock valued at $7,249,000 after acquiring an additional 25,862 shares during the last quarter. QRG Capital Management Inc. bought a new position in shares of PTC Therapeutics in the 3rd quarter valued at about $2,090,000. Finally, Brummer Multi Strategy AB bought a new position in shares of PTC Therapeutics in the 3rd quarter valued at about $1,175,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.